ROIVANT SCIENCES LTD. Research and Development in Process
ROIVANT SCIENCES LTD. (ROIV) reported Research and Development in Process of $87.75 million for the 12-month period ending 2023-03-31, per its 10-K filed 2023-06-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-06-28
- ROIVANT SCIENCES LTD. research and development in process for the quarter ending 2023-03-31 was $0.00.
- ROIVANT SCIENCES LTD. research and development in process for the quarter ending 2022-12-31 was $87.75M, a 1334.74% increase year-over-year.
- ROIVANT SCIENCES LTD. research and development in process for the quarter ending 2022-03-31 was $0.00.
- ROIVANT SCIENCES LTD. research and development in process for the quarter ending 2021-12-31 was $6.12M, a 73.86% decline year-over-year.
- ROIVANT SCIENCES LTD. research and development in process for fiscal 2023 was $87.75M, a 12.18% increase from fiscal 2022.
- ROIVANT SCIENCES LTD. research and development in process for fiscal 2022 was $78.22M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $87.75M derived: sum of 2 quarters · filed 2023-06-28 | $87.75M 10-K · filed 2023-06-28 | |
| 2022-12-31 | $87.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $87.75M 10-Q · filed 2023-02-13 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | |||
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $6.12M derived: sum of 2 quarters · filed 2023-06-28 | $78.22M 10-K · filed 2023-06-28 | |
| 2021-12-31 | $6.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $78.22M 10-Q · filed 2023-02-13 | ||
| 2021-09-30 | $72.11M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $23.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | $65.17M 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $41.78M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |